Article Text

Download PDFPDF
Physical properties of commercially available formulations of triamcinolone acetonide
  1. L K Chang,
  2. N L Gomes,
  3. J Zhou,
  4. S Chang
  1. Department of Ophthalmology, Columbia University College of Physicians and Surgeons, New York, USA
  1. Correspondence to Dr L Chang, Columbia University, 635 W 165th Street, New York, NY 10032, USA; lc2459{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Triamcinolone acetonide (TA) has been used extensively in the treatment of intraocular inflammation and macular oedema, and for the intraoperative visualisation of vitreous and epiretinal membranes during vitrectomy.1 In the USA, the most commonly used commercially available formulation of TA contains 0.022% benzyl alcohol as a preservative in the vehicle (Kenalog-40; Bristol-Myers-Squibb, Peapack, New Jersey). There is evidence that this preservative may have toxic effects on the retina.2 In an attempt to reduce solvent concentrations and the potential toxicity, methods of resuspending TA have been described.3 4 Recently, triamcinolone acetonide injectable suspension (Triesence, Alcon Laboratories, Fort Worth, Texas) has become commercially available and is approved by the United States Food and Drug Administration specifically for intraocular use. We compared physical properties of TA and TA injectable suspension (TAIS) that may affect the intraocular behaviour of these formulations.

Methods and materials

TA and PFTA crystals …

View Full Text


  • Funding LKC is supported in part by the Heed Ophthalmic Foundation.

  • Competing interests SC serves on the scientific advisory board of Alcon Laboratories.

  • Provenance and Peer review Not commissioned; externally peer reviewed.